Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
aflibercept + FOLFIRI
DRUG
3 trials
Sponsors
CR-CSSS Champlain-Charles-Le Moyne
, Recherche clinique
, Yonsei University
Conditions
Metastatic Colon Cancer
Metastatic Colorectal Cancer
Recurrent or Metastatic Colorectal Cancer
Phase 2
Study to Identify Biomarkers of Clinical Response to Aflibercept in Patients With Metastatic Colorectal Cancer
Terminated
NCT02045030
CR-CSSS Champlain-Charles-Le Moyne
Metastatic Colorectal Cancer
Start: 2014-01-31
End: 2016-11-30
Updated: 2016-11-16
Phase 4
Plasma Biomarker for Aflibercept in Advanced Colorectal Cancer
NCT04810585
Yonsei University
Recurrent or Metastatic Colorectal Cancer
Start: 2020-04-20
End: 2025-10-31
Target: 153
Updated: 2021-03-23
Unknown Phase
ZETA : Prospective Observational Study
Completed
NCT03730558
Recherche clinique
Metastatic Colon Cancer
Start: 2017-11-08
End: 2021-11-08
Updated: 2025-01-22
Related Papers
Efficacy and circulating protein biomarkers of second-line aflibercept plus FOLFIRI according to prior bevacizumab or cetuximab treatment in advanced colorectal cancer (KCSG CO21-21).
Journal of Clinical Oncology
2026-05-27